Phase 0 studies using microdosing can save time and lower costs when compared to phase I studies, as well reducing the exposure of humans and animals to new chemical entities. Of course, such studies cannot be a substitute for clinical trials at therapeutic doses.

As with other first-in-human studies Eoltinplas Pharmaceutical Company and CTC have partnered to take responsibility for the full program reducing the complexity.